Empagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH
International Journal of Molecular Sciences 22:6332, 2021
Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis
Liver International 41(8):1853-1866, 2021
Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis
British Journal of Pharmacology 178(12):2412-2423, 2021
Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative
Liver International 40:2860-2876, 2020
Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis
BMC Gastroenterology 20:210, 2020
Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis
Nature Metabolism 2(5):413–431, 2020